Reviva Pharmaceutcls Hldgs Inc Financials

RVPH

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Reviva Pharmaceutcls Hldgs Inc (RVPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

0/9

Reviva Pharmaceutcls Hldgs Inc passes 0 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

1.12x

For every $1 of reported earnings, Reviva Pharmaceutcls Hldgs Inc generates $1.12 in operating cash flow (-$33.5M OCF vs -$29.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1665.1x

Reviva Pharmaceutcls Hldgs Inc earns $-1665.1 in operating income for every $1 of interest expense (-$30.8M vs $18K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

N/A

Free Cash Flow

N/A

Net Income

-$29.9M

YoY+23.8%

Reviva Pharmaceutcls Hldgs Inc reported -$29.9M in net income in fiscal year 2024. This represents an increase of 23.8% from the prior year.

EPS (Diluted)

N/A

Cash & Debt

$13.5M

YoY-42.3%

5Y CAGR+830.7%

Reviva Pharmaceutcls Hldgs Inc held $13.5M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

47M

YoY+66.8%

5Y CAGR+41.3%

Reviva Pharmaceutcls Hldgs Inc had 47M shares outstanding in fiscal year 2024. This represents an increase of 66.8% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$22.9M

YoY-27.1%

5Y CAGR+159.2%

Reviva Pharmaceutcls Hldgs Inc invested $22.9M in research and development in fiscal year 2024. This represents a decrease of 27.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

RVPH Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$22.9M-27.1%	$31.4M+37.4%	$22.9M+371.4%	$4.9M+1543.8%	$295K+50.8%	$196K
SG&A Expenses	$7.9M-2.4%	$8.1M+50.9%	$5.4M+2.0%	$5.3M+145.5%	$2.1M+1081.3%	$181K
Operating Income	-$30.8M+22.0%	-$39.5M-39.9%	-$28.2M-179.4%	-$10.1M-315.0%	-$2.4M-546.0%	-$377K
Interest Expense	$18K-45.2%	$34K	N/A	$0-100.0%	$1.5M+209.6%	$469K
Income Tax	$20K+15.1%	$17K-18.4%	$21K+246.1%	$6K+650.5%	$8000.0%	$800
Net Income	-$29.9M+23.8%	-$39.3M-38.9%	-$28.3M-231.6%	-$8.5M-125.2%	-$3.8M-346.8%	-$847K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.1M-42.8%	$3.7M-9.5%	$4.1M-40.0%	$6.9M+22.8%	$5.6M-3.4%	$5.8M	N/A	$9.6M
SG&A Expenses	$1.9M-19.2%	$2.3M-3.2%	$2.4M+51.1%	$1.6M-37.0%	$2.5M+19.0%	$2.1M	N/A	$2.0M
Operating Income	-$4.0M+33.6%	-$6.1M+7.1%	-$6.5M+22.7%	-$8.5M-4.1%	-$8.1M-2.6%	-$7.9M	N/A	-$11.6M
Interest Expense	$3K-45.7%	$5K-58.7%	$12K+125.8%	$5K-0.1%	$5K+47.8%	$3K	N/A	$6K
Income Tax	$3K-64.3%	$8K+52.6%	$5K	$0-100.0%	$7K-0.1%	$7K	N/A	$12K
Net Income	-$4.0M+33.7%	-$6.1M+5.9%	-$6.4M+23.1%	-$8.4M-6.4%	-$7.9M-5.7%	-$7.4M	N/A	-$11.3M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RVPH Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$15.5M-34.6%	$23.7M+25.2%	$18.9M-39.7%	$31.4M+258.4%	$8.8M+336910.7%	$3K
Current Assets	$14.7M-38.0%	$23.7M	N/A	N/A	$44K-70.5%	$150K
Cash & Equivalents	$13.5M-42.3%	$23.4M+26.2%	$18.5M-37.6%	$29.7M+238.9%	$8.8M+4538999.5%	$193
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$14.7M-18.3%	$18.0M+70.8%	$10.5M+287.5%	$2.7M-17.6%	$3.3M-51.6%	$6.8M
Current Liabilities	$14.6M-15.0%	$17.2M+72.4%	$10.0M+324.9%	$2.3M+75.9%	$1.3M+1231.4%	$100K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$813K-85.8%	$5.7M-31.9%	$8.4M-70.7%	$28.7M+424.8%	$5.5M+180.2%	-$6.8M
Retained Earnings	-$164.3M-22.3%	-$134.4M-41.3%	-$95.1M-42.3%	-$66.8M-14.6%	-$58.3M-6.9%	-$54.5M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$14.3M+23.2%	$11.6M+64.4%	$7.1M-54.4%	$15.5M+92.5%	$8.1M-40.3%	$13.5M-43.1%	$23.7M+340.0%	$5.4M
Current Assets	$13.5M+24.9%	$10.8M+72.8%	$6.3M-57.4%	$14.7M+103.0%	$7.2M	N/A	$23.7M	N/A
Cash & Equivalents	$13.2M+27.2%	$10.4M+95.9%	$5.3M-60.8%	$13.5M+118.1%	$6.2M-48.4%	$12.0M-48.8%	$23.4M+370.0%	$5.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.8M-19.1%	$12.1M+4.8%	$11.5M-21.5%	$14.7M+4.2%	$14.1M-5.0%	$14.8M-17.5%	$18.0M-1.2%	$18.2M
Current Liabilities	$9.7M-19.4%	$12.1M+4.9%	$11.5M-21.2%	$14.6M+4.7%	$13.9M-3.8%	$14.5M-15.6%	$17.2M-0.9%	$17.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.5M+1090.9%	-$459K+89.7%	-$4.5M-648.9%	$813K+113.4%	-$6.0M-348.9%	-$1.3M-123.5%	$5.7M+144.6%	-$12.8M
Retained Earnings	-$180.8M-2.3%	-$176.8M-3.5%	-$170.7M-3.9%	-$164.3M-9.8%	-$149.6M-5.5%	-$141.8M-5.5%	-$134.4M-7.5%	-$125.0M

RVPH Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$33.5M-18.4%	-$28.3M-49.4%	-$19.0M-77.7%	-$10.7M-162.3%	-$4.1M-1761.6%	-$218K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$5.7M
Financing Cash Flow	$23.7M-28.7%	$33.2M+325.7%	$7.8M-75.3%	$31.6M+146.3%	$12.8M+12726.9%	$100K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$6.3M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$5.6M-11.5%	-$5.0M+38.8%	-$8.2M+10.0%	-$9.1M-7.4%	-$8.5M+27.7%	-$11.7M-32.1%	-$8.9M-43.6%	-$6.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$8.4M-16.6%	$10.1M+138630.0%	$7K-100.0%	$17.0M+534.8%	$2.7M+707.4%	$332K-98.8%	$27.3M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RVPH Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	11.5%
Return on Assets	-193.0%-27.3pp	-165.7%-16.3pp	-149.3%-122.2pp	-27.1%+16.0pp	-43.2%+32527.3pp	-32570.5%
Current Ratio	1.01-0.4	1.38	N/A	N/A	0.03-1.5	1.50
Debt-to-Equity	18.08+14.9	3.14+1.9	1.25+1.2	0.09-0.5	0.60+1.6	-1.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-28.0%+24.1pp	-52.0%+38.9pp	-90.9%+18.8pp	-109.7%-12.0pp	-97.6%-42.5pp	-55.1%	N/A	-210.6%
Current Ratio	1.39+0.5	0.90+0.4	0.54-0.5	1.01+0.5	0.52	N/A	1.38	N/A
Debt-to-Equity	2.15+28.5	-26.34-23.8	-2.59-20.7	18.08+20.4	-2.33+8.7	-11.03-14.2	3.14+4.6	-1.42
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Kezar Life Sciences KZR

$46.1M

Tenax Therapeutics Inc TENX

$79.0M

Neuphoria Therapeutics Inc NEUP

$21.8M

LakeShore Biopharma Co., Ltd LSB

$25.8M

OnKure Therapeutics OKUR

$32.8M

Frequently Asked Questions

Is Reviva Pharmaceutcls Hldgs Inc profitable?

No, Reviva Pharmaceutcls Hldgs Inc (RVPH) reported a net income of -$29.9M in fiscal year 2024.

What is Reviva Pharmaceutcls Hldgs Inc's operating cash flow?

Reviva Pharmaceutcls Hldgs Inc (RVPH) generated -$33.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Reviva Pharmaceutcls Hldgs Inc's total assets?

Reviva Pharmaceutcls Hldgs Inc (RVPH) had $15.5M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Reviva Pharmaceutcls Hldgs Inc spend on research and development?

Reviva Pharmaceutcls Hldgs Inc (RVPH) invested $22.9M in research and development during fiscal year 2024.

How many shares does Reviva Pharmaceutcls Hldgs Inc have outstanding?

Reviva Pharmaceutcls Hldgs Inc (RVPH) had 47M shares outstanding as of fiscal year 2024.

What is Reviva Pharmaceutcls Hldgs Inc's current ratio?

Reviva Pharmaceutcls Hldgs Inc (RVPH) had a current ratio of 1.01 as of fiscal year 2024, which is considered adequate.

What is Reviva Pharmaceutcls Hldgs Inc's debt-to-equity ratio?

Reviva Pharmaceutcls Hldgs Inc (RVPH) had a debt-to-equity ratio of 18.08 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Reviva Pharmaceutcls Hldgs Inc's return on assets (ROA)?

Reviva Pharmaceutcls Hldgs Inc (RVPH) had a return on assets of -193.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Reviva Pharmaceutcls Hldgs Inc's cash runway?

Based on fiscal year 2024 data, Reviva Pharmaceutcls Hldgs Inc (RVPH) had $13.5M in cash against an annual operating cash burn of $33.5M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Reviva Pharmaceutcls Hldgs Inc's Piotroski F-Score?

Reviva Pharmaceutcls Hldgs Inc (RVPH) has a Piotroski F-Score of 0 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Reviva Pharmaceutcls Hldgs Inc's earnings high quality?

Reviva Pharmaceutcls Hldgs Inc (RVPH) has an earnings quality ratio of 1.12x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Reviva Pharmaceutcls Hldgs Inc cover its interest payments?

Reviva Pharmaceutcls Hldgs Inc (RVPH) has an interest coverage ratio of -1665.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.